DE69840962D1 - ADJUVANT QS-21 CONTAINING COMPOSITIONS WITH POLYSORBATE OR CYCLODEXTRIN AS AID - Google Patents

ADJUVANT QS-21 CONTAINING COMPOSITIONS WITH POLYSORBATE OR CYCLODEXTRIN AS AID

Info

Publication number
DE69840962D1
DE69840962D1 DE69840962T DE69840962T DE69840962D1 DE 69840962 D1 DE69840962 D1 DE 69840962D1 DE 69840962 T DE69840962 T DE 69840962T DE 69840962 T DE69840962 T DE 69840962T DE 69840962 D1 DE69840962 D1 DE 69840962D1
Authority
DE
Germany
Prior art keywords
adjuvant
compositions
polysorbate
cyclodextrin
aid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840962T
Other languages
German (de)
Inventor
Charlotte Kensil
Gerald A Beltz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenus Inc
Original Assignee
Antigenics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antigenics LLC filed Critical Antigenics LLC
Application granted granted Critical
Publication of DE69840962D1 publication Critical patent/DE69840962D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Certain novel compositions of the adjuvant saponin QS-21 having improved properties are disclosed. The compositions of the present invention are designed (1) to minimize the lytic effects of QS-21, (2) to improve the tolerance of QS-21 containing formulations in humans or other animals, (3) to stabilize the QS-21 from alkaline hydrolysis and/or (4) to maintain the high adjuvant potency of the QS-21 product. These compositions may be employed with vaccines comprising proteins or peptides, polysaccharides, lipids, or nucleic acids.
DE69840962T 1997-08-29 1998-08-28 ADJUVANT QS-21 CONTAINING COMPOSITIONS WITH POLYSORBATE OR CYCLODEXTRIN AS AID Expired - Lifetime DE69840962D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725597P 1997-08-29 1997-08-29
PCT/US1998/017940 WO1999010008A1 (en) 1997-08-29 1998-08-28 Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient

Publications (1)

Publication Number Publication Date
DE69840962D1 true DE69840962D1 (en) 2009-08-20

Family

ID=22009474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840962T Expired - Lifetime DE69840962D1 (en) 1997-08-29 1998-08-28 ADJUVANT QS-21 CONTAINING COMPOSITIONS WITH POLYSORBATE OR CYCLODEXTRIN AS AID

Country Status (10)

Country Link
US (2) US6645495B1 (en)
EP (2) EP1009429B1 (en)
JP (3) JP5220248B2 (en)
AT (1) ATE435661T1 (en)
AU (1) AU734180B2 (en)
CA (2) CA2654522C (en)
DE (1) DE69840962D1 (en)
ES (2) ES2500490T3 (en)
HK (1) HK1129846A1 (en)
WO (1) WO1999010008A1 (en)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2500490T3 (en) * 1997-08-29 2014-09-30 Antigenics Inc. Compositions comprising adjuvant QS-21 and polysorbate or cyclodextrin as excipient
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
WO2000009159A1 (en) 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
PT1187629E (en) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa ADJUVANT COMPOSITION THAT UNDERSTANDS SAPONIN AND AN IMMUNOSTIMULATOR OLIGONUCLEOTIDE
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU5793600A (en) * 1999-09-22 2001-03-29 Baker Hughes Incorporated Hydraulic fracturing using non-ionic surfactant gelling agent
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2001085932A2 (en) 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
PT2266603E (en) 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Tumour vaccines
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
AU2002218535A1 (en) * 2000-12-12 2002-06-24 Japan Tobacco Inc. Pharmaceutical composition containing an active with a hemolytic action and a surfactant
DE10144030A1 (en) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Composition containing 4-piperazino-benzoylguanidine derivative, useful e.g. for treating cardiac infarction, containing component to improve local tolerance, e.g. beta-cyclodextrin derivative or polymer
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PL376792A1 (en) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1687022A4 (en) 2003-11-12 2008-02-13 Medical Res Council Renta: an hiv immunogen and uses thereof
DE602005025342D1 (en) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa VACCINE COMPOSITIONS WITH VIRUSOMES AND A SAPONIN ADJUVANS
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP1811839A4 (en) * 2004-11-18 2008-08-06 Univ Rochester Methods and compositions related to esculentoside a
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US7622121B2 (en) * 2005-09-21 2009-11-24 New York University Heat shock proteins from Mycobacterium leprae and uses thereof
WO2007079193A2 (en) 2005-12-30 2007-07-12 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
DK2399602T3 (en) 2006-06-02 2015-02-23 Int Aids Vaccine Initiative HIV-1 clade-A CONSENSUS SEQUENCES, ANTIGENS AND TRAN GENES
TR201807756T4 (en) 2006-09-26 2018-06-21 Infectious Disease Res Inst Vaccine composition containing synthetic adjuvant.
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
MX2009009342A (en) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Novel method and compositions.
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
KR101540920B1 (en) * 2007-07-26 2015-08-03 사노피 파스퇴르 리미티드 Antigen-adjuvant compositions and methods
PT2182983E (en) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
EP2190470B1 (en) 2007-08-13 2017-12-13 GlaxoSmithKline Biologicals SA Vaccines
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan Nanoemulsion vaccines
TW201010719A (en) * 2008-08-19 2010-03-16 Wyeth Corp Immunological composition
AU2009296458A1 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
CN102596243B (en) 2009-06-16 2015-10-21 密执安大学评议会 Nanoemulsion vaccines
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
KR101746880B1 (en) 2009-09-10 2017-06-14 메리얼 인코포레이티드 New vaccine formulations comprising saponin-containing adjuvants
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
BR112013004582A2 (en) 2010-09-27 2016-09-06 Crucell Holland Bv method for inducing an immune response in a subject against a parasite antigen that causes malaria
KR102007444B1 (en) 2011-04-25 2019-08-06 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 Truncated hiv envelope proteins(env), methods and compositions related thereto
HUE037408T2 (en) 2011-06-10 2018-08-28 Univ Oregon Health & Science Cmv glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
SG11201400193SA (en) 2011-09-16 2014-05-29 Ucb Pharma Sa Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
KR102024066B1 (en) 2011-11-23 2019-09-24 비오벤 쓰리 리미티드 Recombinant proteins and their therapeutic uses
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
CN104363892A (en) 2012-02-07 2015-02-18 传染性疾病研究院 Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
ES2807173T3 (en) 2012-09-10 2021-02-22 Int Aids Vaccine Initiative Broadly Neutralizing HIV-1 Antibody Immunogens, Generation Methods, and Uses
CN111978409B (en) 2013-03-15 2024-01-26 因斯瑞拜奥有限公司 Self-assembled synthetic proteins
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP6306700B2 (en) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロUniversity of Oslo Modified albumin and use thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
US11801223B2 (en) 2013-12-31 2023-10-31 Access To Advanced Health Institute Single vial vaccine formulations
WO2015163488A1 (en) 2014-04-25 2015-10-29 Ajinomoto Co., Inc. Immunostimulating agent
WO2015171975A1 (en) 2014-05-09 2015-11-12 The Regents Of The University Of Michigan Use of modified banana lectin in purification of glycoproteins
SG11201609721WA (en) 2014-05-28 2016-12-29 Agenus Inc Anti-gitr antibodies and methods of use thereof
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
WO2016057921A1 (en) 2014-10-10 2016-04-14 Baker Jr James R Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016141320A2 (en) 2015-03-05 2016-09-09 Northwestern University Non-neuroinvasive viruses and uses thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
KR20180006945A (en) 2015-05-13 2018-01-19 아게누스 인코포레이티드 Vaccine for cancer treatment and prevention
CN114605548A (en) 2015-09-01 2022-06-10 艾吉纳斯公司 anti-PD-1 antibodies and methods of use thereof
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
WO2017073797A1 (en) 2015-10-28 2017-05-04 Ajinomoto Co., Inc. Immunostimulating agent
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
CR20180445A (en) 2016-03-14 2019-02-08 Univ Oslo IMMUNOGLOBULINS DESIGNED BY GENETIC ENGINEERING WITH UNION ALTERED TO FCRN
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
CN109476751B (en) 2016-05-27 2024-04-19 艾吉纳斯公司 Anti-TIM-3 antibodies and methods of use thereof
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
CA3034124A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
AU2017343621B2 (en) 2016-10-11 2021-12-02 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
MX2019008346A (en) 2017-01-13 2019-09-09 Agenus Inc T cell receptors that bind to ny-eso-1 and methods of use thereof.
MX2019012223A (en) 2017-04-13 2019-12-09 Agenus Inc Anti-cd137 antibodies and methods of use thereof.
TWI805582B (en) 2017-05-01 2023-06-21 美商艾吉納斯公司 Anti-tigit antibodies and methods of use thereof
BR112020001045A2 (en) 2017-07-18 2020-09-08 In3Bio Ltd. synthetic proteins and therapeutic uses thereof
CA3073055A1 (en) 2017-09-04 2019-03-07 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
WO2019048928A1 (en) 2017-09-07 2019-03-14 University Of Oslo Vaccine molecules
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo Vaccine molecules
CN111315406A (en) 2017-09-08 2020-06-19 传染病研究所 Liposome formulations comprising saponins and methods of use thereof
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
JP2021522239A (en) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド Heat shock protein-binding peptide composition and how to use it
KR20210056953A (en) 2018-05-30 2021-05-20 트랜슬레이트 바이오 인코포레이티드 Messenger RNA vaccine and uses thereof
CN112638936A (en) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 Adenovirus polynucleotides and polypeptides
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
MX2021001479A (en) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Processes and vaccines.
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
CN113573730A (en) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 Hepatitis B immunization protocols and compositions
CN114340665A (en) 2019-05-25 2022-04-12 传染病研究所 Compositions and methods for spray drying adjuvant vaccine emulsions
BR112021026132A2 (en) 2019-06-25 2022-02-08 In3Bio Ltd Stabilized chimeric synthetic proteins and therapeutic uses thereof
CA3152027A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
EP4058581A1 (en) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
US20210338804A1 (en) 2020-02-21 2021-11-04 International Aids Vaccine Initiative Inc. Vaccine Compositions For Preventing Coronavirus Disease
EP4115950A4 (en) 2020-03-02 2024-03-13 Cyclochem Bio Co., Ltd. Intestinal tract function improving agent
EP4255919A2 (en) 2020-12-02 2023-10-11 GlaxoSmithKline Biologicals S.A. Donor strand complemented fimh
US20240156935A1 (en) 2021-03-31 2024-05-16 Vib Vzw Vaccine Compositions for Trypanosomatids
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
WO2024145204A1 (en) * 2022-12-29 2024-07-04 Q-Vant Biosciences, Inc. Modified qs-21 compositions and processes for producing the same and uses therefor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
DE3446515A1 (en) * 1984-12-20 1986-06-26 Behringwerke Ag, 3550 Marburg OIL ADJUVED VACCINE AND METHOD FOR THE PRODUCTION THEREOF
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
ZA872532B (en) * 1986-04-21 1987-11-25 Akzo Nv Combined vaccine
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
NL9002314A (en) * 1990-10-23 1992-05-18 Nederlanden Staat IMMUNOGENE COMPLEXES, IN PARTICULAR ISCOMS.
ZA927037B (en) * 1991-09-30 1993-03-29 Akzo Nv Respiratory disease vaccine for cats.
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
JP2510943B2 (en) * 1993-06-07 1996-06-26 株式会社ドクターマインツ Slimming food
DK0724433T3 (en) * 1993-10-22 1999-08-30 Genentech Inc Process for preparing microspheres with a fluidized bed drying step
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688772A (en) * 1994-08-01 1997-11-18 University Of Saskatchewan Quinoa saponin compositions and methods of use
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
BE1008978A5 (en) * 1994-12-27 1996-10-01 Solvay Adjuvants for vaccines.
KR0184779B1 (en) * 1995-04-13 1999-04-01 성재갑 Saponine variants isolated and purified from quillaja saponaria
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
CA2290646C (en) * 1997-05-20 2008-03-11 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
ES2500490T3 (en) * 1997-08-29 2014-09-30 Antigenics Inc. Compositions comprising adjuvant QS-21 and polysorbate or cyclodextrin as excipient

Also Published As

Publication number Publication date
EP2050465A3 (en) 2009-09-02
CA2654522C (en) 2014-01-28
AU9210798A (en) 1999-03-16
ES2500490T3 (en) 2014-09-30
ES2327693T3 (en) 2009-11-02
JP2011162559A (en) 2011-08-25
JP2001513575A (en) 2001-09-04
AU734180B2 (en) 2001-06-07
CA2654522A1 (en) 1999-03-04
EP1009429B1 (en) 2009-07-08
CA2302522C (en) 2010-08-17
JP5220248B2 (en) 2013-06-26
HK1129846A1 (en) 2009-12-11
US6645495B1 (en) 2003-11-11
WO1999010008A1 (en) 1999-03-04
US20050191310A1 (en) 2005-09-01
EP1009429A1 (en) 2000-06-21
EP2050465B1 (en) 2014-06-11
CA2302522A1 (en) 1999-03-04
JP2009197014A (en) 2009-09-03
EP2050465A2 (en) 2009-04-22
ATE435661T1 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
ATE435661T1 (en) COMPOSITIONS CONTAINING ADJUVANT QS-21 WITH POLYSORBATE OR CYCLODEXTRIN AS AID
PT770397E (en) COMBINATION VACCINE AGAINST NEWCASTLE DISEASE VIRUS
HK1046016B (en) Recombinant gelatin in vaccines
FR2792202B1 (en) LUPINE PEPTIDE EXTRACT AND PHARMACEUTICAL OR COSMETIC OR NUTRACEUTICAL COMPOSITION COMPRISING SUCH EXTRACT
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
BR9910973A (en) Vaccine
ATE116993T1 (en) SAPONIN REMEDIES.
FI953442A (en) Freeze-dried spheres containing gonadotropin
PT789590E (en) IMMUNOPOTATION INDUCED BY QUITOSAN
DE69828801D1 (en) PEPTIDE DERIVED FROM THE BINDING (G) PROTEIN OF THE RESPIRATORY SYNZYTIALVIRUS
FR2692282B1 (en) CLONING OF THE GENE ENCODING THE PROTEIN GP28.5 OF T. GONDII; PEPTIDE FRAGMENTS FROM SUCH PROTEIN AND THEIR APPLICATIONS.
ES2096727T3 (en) COSMETIC AND PHARMACEUTICAL PRODUCTS CONTAINING EXTENSINS.
ES2119779T3 (en) SOLUBILIZATION OF PROTEINS IN ACTIVE FORMS.
ES2170144T3 (en) VARIANTS THAT DO NOT EMPALMATE FROM GP350 / 220.
DK0588177T3 (en) Interferon-alpha / beta-binding protein, preparation thereof and pharmaceutical preparations containing the protein
NO942323L (en) Soy protein or hydrolysates in pharmaceutical compositions for the protection of bioactive peptides against enzymatic inactivation
DE69637435D1 (en) SAPONIN COMPOSITIONS AND ITS USE
ES2017900T3 (en) DERIVATIVES OF THE ACID TIAZOLIDIN-4-CARBOXILICO, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
ATE353226T1 (en) ADJUVANT COMPOSITION CONTAINING FHA OR AN FHA FRAGMENT IN FREE FORM
NO911788D0 (en) GALENIC Aqueous Preparations Of Erythropoietin.
AP9801399A0 (en) Zona pellucida proteins for contraception.
TR200002611T2 (en) Beta-lipotropin and its uses
DE3560262D1 (en) Hexapeptide, process for its preparation and pharmaceutical compositions thereof
DE69130953D1 (en) IMMUNE REINFORCEMENT OF VACCINE, ESPECIALLY VACCINE AGAINST PIG PLEUROPNEUMONIA
IT1153208B (en) PROCEDURE FOR THE EXTRACTION OF NITROGEN SUBSTANCES, IN PARTICULAR PROTEINS AND / OR AMINO ACIDS FROM VEGETABLE SUBSTANCES, IN PARTICULAR FROM BY-PRODUCTS OF SOY PROCESSING

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ANTIGENICS INC., LEXINGTON, MASS., US

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: JONES DAY RECHTSANWAELTE PATENTANWAELTE, 80538 MUE

8328 Change in the person/name/address of the agent

Representative=s name: DERZEIT KEIN VERTRETER BESTELLT